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This study was conducted to explore the effects of interferon tau (IFNT) on the intestinal microbiota and expression of interleukin
17 (IL-17) in the intestine of mice. IFNT supplementation increased microbial diversity in the jejunum and ileum but decreased
microbial diversity in the feces. IFNT supplementation influenced the composition of the intestinal microbiota as follows: (1)
decreasing the percentage of Firmicutes and increasing Bacteroidetes in the jejunum and ileum; (2) enhancing the percentage
of Firmicutes but decreasing Bacteroidetes in the colon and feces; (3) decreasing Lactobacillus in the jejunum and ileum; (4)
increasing the percentage of Blautia, Bacteroides, Alloprevotella, and Lactobacillus in the colon; and (5) increasing the percentage
of Lactobacillus, Bacteroides, and Allobaculum, while decreasing Blautia in the feces. Also, IFNT supplementation decreased
the expression of IL-17 in the intestines of normal mice and of an intestinal pathogen infected mice. In conclusion, IFNT
supplementation modulates the intestinal microbiota and intestinal IL-17 expression, indicating the applicability of IFNT to treat
the intestinal diseases involving IL-17 expression and microbiota.
1. Introduction
Interferon tau (IFNT) is produced by trophectoderm cells
of conceptuses of ruminant species and is the maternal
recognition of the pregnancy signal. Besides its critical roles
in implantation and establishment of pregnancy in ruminants
[1, 2], it has a plethora of physiological functions in various
cell types such as macrophages, lymphocytes, and epithelial
cells in humans andmice [3–5]. It is a type I interferon (IFN),
which includes IFN alpha (IFNA), IFN beta (IFNB), IFN
delta (IFND), and IFN omega (IFNW). After binding to a
common receptor, IFNA receptor 1 (IFNAR1), and IFNAR2,
type I IFNs affect the production of inflammatory cytokines
such as interleukin- (IL-) 1𝛽 and tumor necrosis factor 𝛼
(TNF-𝛼) [6, 7]. Thus, type I IFNs have widely recognized
roles in inflammatory diseases, such as experimental aller-
gic encephalomyelitis, multiple sclerosis, and spontaneous
autoimmune diabetes [5, 8–10]. Notably, unlike other mem-
bers of type I IFN family, IFNT has few adverse effects and
low cytotoxicity even at high dosages [11, 12], suggesting its
therapeutic potential as an alternative to other type I IFNs due
to its anti-inflammatory effects. Recent compelling findings
about the anti-inflammatory effects of IFNT include lower
NLRP3 (nucleotide-binding oligomerization domain-like
receptor, pyrin domain-containing 3) inflammasome-driven
IL-1𝛽 secretion by human macrophages [4], mitigation of
obesity-associated systemic tissue inflammation in mice [5],
and promotion of Th2 biased immune response in mice [9].
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The influence of IFNT on intestinal microbiota is un-
known.The intestinalmicrobiota provides important benefits
for the development of immune responses; however, the
disturbances in the intestinal microbiota are associated with
numerous chronic inflammatory diseases [13, 14]. Also, the
effect of IFNT on expression of IL-17 in the intestine is
not known. The potential effect of IFNT on expression
of IL-17 is important as IL-17 promotes local chemokine
production to recruit monocytes and neutrophils to sites of
inflammation that leads to development and pathogenesis of
various autoimmune diseases, including rheumatoid arthri-
tis, psoriasis vulgaris, multiple sclerosis, and inflammatory
bowel diseases [15, 16]. In this study, the intestinal microbiota
and expression of IL-17 in the intestine were explored after
two weeks of IFNT supplementation in a mouse model. The
hypothesis is that IFNT supplementation alters intestinal
microbiota and intestinal innate immunity in mouse model.
2. Materials and Methods
2.1. Bacterial Strains. This study used the Escherichia coli
F4-producing strain W25K (hereafter referred as ETEC;
O149:K91, K88ac; LT, STb, EAST), which was originally
isolated from a piglet with diarrhea [17].
2.2. IFNT Supplementation for Mice. This study was con-
ducted according to the guidelines of the Laboratory Animal
Ethical Commission of the Chinese Academy of Sciences.
ICR (Institute for Cancer Research) mice (six weeks of
age) were purchased from SLAC Laboratory Animal Central
(Changsha, China). The mice were housed individually in a
pathogen-free animal vivarium (temperature, 25∘C; relative
humidity, 53%; 12 h dark/12 h light) and had free access to
a standard rodent diet [18] and drinking water. After three
days of accommodation, mice were assigned randomly into
two groups (IFNT and control; 𝑛 = 10/group). Mice in
the control group were fed the basal diet [18] and normal
water, while mice in IFNT group were fed the basal diet and
water containing recombinant IFNT (40 𝜇g/L) for two weeks.
The effective supplemental dosage of IFNT was established
in previous study [5, 19]. At the end of the two weeks of
experimental period, mice were sacrificed to collect contents
of the lumens of the jejunum, ileum, and colon, as well as
feces. The tissues including jejunum, ileum, and colon were
also collected. Feed and water intake and body weight gain
were monitored throughout the experiment. Samples were
collected and stored at −80∘C until processed.
2.3. ETEC Infection of Mice. After three days of accommo-
dation to the conditions of the vivarium, ICR mice were
assigned randomly into two groups (ETEC and IFNT+ETEC;
𝑛 = 10/group).Mice in IFNT+ETEC groupwere fed the basal
diet and recombinant IFNT-supplemented water (40 𝜇g/L)
for two weeks, while mice in ETEC group were fed the basal
diet and had normal water. After two weeks of feeding, mice
in both groupswere inoculatedwith 108 CFUsof ETECW25K
by oral gavage. At 6 hours after infection, all active mice were
sacrificed to collect the jejunum, and the samples were stored
at −80∘C until processed.
2.4. 16S rDNA Sequencing with Illumina MiSeq Sequenc-
ing. DNA was extracted from the luminal contents of the
jejunum, ileum and colon, and feces using the Qiagen
QIAamp DNA Stool Mini Kit according to the protocol
for isolation of DNA. Equal amounts of DNA from six
different mice were pooled to generate one common sample
for each type of sample (i.e., control versus IFNT, intestinal
source, and feces). The V4-V5 region of the bacterial 16S
ribosomal RNA gene was amplified by PCR using primers
515F 5󸀠-barcode-GTGCCAGCMGCCGCGG-3󸀠 and 907R 5󸀠-
CCGTCAATTCMTTTRAGTTT-3󸀠, where barcode is an
eight-base sequence unique to each sample. Illumina MiSeq
sequencing and general data analyses were performed by a
commercial company (Biotree, Shanghai, China). Miseq PE
Libraries,Miseq Sequencing, and further analyses were based
on previous work [20].
2.5. RT-PCR. Total RNA was isolated from liquid nitrogen
frozen and ground jejunum, ileum, and colon using TRIZOL
regent (Invitrogen, USA) and then treated with DNase I
(Invitrogen, USA) according to the manufacturer’s instruc-
tions. Synthesis of the first strand (cDNA) was performed
using oligo (dT) 20 and Superscript II reverse transcriptase
(Invitrogen, USA). Primers were selected according to pre-
vious references [18, 21]. 𝛽-actin was used as an internal
control to normalize expression of target gene transcripts.The
RT-PCR experiment was conducted according to previous
studies [18, 21].
2.6. Statistical Analyses. Data shown are the means ± the
standard error of the mean (SEM). All statistical analyses
for data were performed using SPSS 16.0 software (Chicago,
IL, USA). Data were analyzed for the two treatment groups
using Student’s t-test. Differences of 𝑃 < 0.05 are considered
significant.
3. Results
3.1. IFNT Treatment Increases Feed Intake. To investigate
the effect of IFNT supplementation on mouse growth per-
formance, feed intake, water intake, and body weight were
monitored in IFNT-supplemented mice and control mice.
With two weeks of IFNT supplementation, the averages for
feed intake and water intake for IFNT-supplemented mice
were significant (𝑃 < 0.05) higher than for control mice
(Figures 1(a) and 1(b)). However, IFNT supplementation had
no significant effect on body weight of mice (Figure 1(c)).
3.2. Changes in Bacterial Diversity of the Intestinal Microbiota
Associated with IFNT Supplementation. To explore the influ-
ence of IFNT supplementation on the intestinal microbiota,
we analyzed the intestinal microbiota at end of two weeks of
IFNT supplementation with 16S rDNA sequencing (Table 1).
For microbiota in the jejunum, both Shannon and Simpson
indices demonstrated that the diversity of microbiota in mice
with IFNT supplementation was higher than the control
mice, while the richness indices (Ace and Chao) suggested
that the community richness in IFNT-supplemented and
control mice was similar (Table 1). For the microbiota in the
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Figure 1: IFNT supplementation has little effect on mouse body weight. (a) Average feed intake in the control and IFNT-supplemented mice
(𝑛 = 10). (b) Average water intake for control and IFNT-supplemented mice (𝑛 = 10). (c) Relative body weight gains for control and IFNT-
supplemented mice (𝑛 = 10). Control mice were fed the basal diet and normal water, while mice in IFNT group were fed the basal diet
and IFNT-supplemented water for two weeks. The asterisk (∗) indicates a statistically significant difference between two treatment groups
(𝑃 < 0.05). Data were analyzed using Student’s t-test.
Table 1: Comparison of phylotype coverage and diversity estimation of the 16S rDNAgene libraries at 97% similarity from the pyrosequencing
analysis.
Group Number of readings Number of OTU Coverage Richness estimator Diversity index
Ace (95% CI) Chao (95% CI) Shannon (95% CI) Simpson (95% CI)
Jejunum
Control 12323 51 99.85% 78 (62–120) 70 (57–108) 1.06 (1.04–1.09) 0.52 (0.51–0.53)
IFNT 15653 64 99.95% 70 (66–83) 67 (65–78) 1.32 (1.30–1.35) 0.44 (0.43–0.45)
Ileum
Control 12442 37 99.89% 52 (42–84) 57 (42–110) 0.73 (0.70–0.75) 0.70 (0.69–0.71)
IFNT 12264 66 99.79% 124 (99–167) 174 (101–400) 1.06 (1.03–1.08) 0.56 (0.55–0.56)
Colon
Control 10327 298 99.58% 323 (311–343) 322 (309–349) 4.32 (4.29–4.35) 0.032 (0.030–0.034)
IFNT 11276 288 99.68% 306 (297–324) 313 (299–345) 4.32 (4.29–4.34) 0.027 (0.026–0.028)
Feces
Control 12613 314 99.69% 336 (326–356) 339 (325–369) 4.39 (4.36–4.41) 0.026 (0.025–0.027)
IFNT 12493 312 99.58% 345 (331–371) 363 (337–414) 4.16 (4.13–4.19) 0.046 (0.044–0.049)
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ileum, the diversity of microbiota (Shannon and Simpson)
and richness indices (Ace) for mice with IFNT supplemen-
tation were higher than that of control mice (Table 1). For the
microbiota in the colon, the diversity of microbiota (Shan-
non) and richness indices (Ace and Chao) were similar for
IFNT-supplemented and control mice (Table 1). For the fecal
microbiota, microbial diversity (Shannon and Simpson) in
mice with IFNT supplementation was lower than for control
mice, while the community richness (Ace and Chao) for
IFNT-supplementedmice was similar to that for controlmice
(Table 1). Collectively, IFNT supplementation increases the
diversity of microbiota in small intestine, while decreasing
the diversity of microbiota in the feces.
3.3. IFNT-Associated Alterations in Intestinal Microbiota. The
taxonomy of the intestinal microbiota was assessed using a
taxon-dependent analysis and theRDP classifier. Seven phyla,
including one candidate division (TM7), were found in the
microbiota of the jejunum for all samples, including six phyla
in the control mice and seven phyla in mice with IFNT
supplementation. Eight phyla were found in the microbiota
of the ileum of all samples, including six phyla in control
mice and seven phyla in mice with IFNT supplementation.
Ten phyla were found in the microbiota of the colon of all
samples, including ten phyla in control mice and eight phyla
in mice with IFNT supplementation. Ten phyla were found
in the microbiota of the feces of all samples, including nine
phyla in control mice and ten phyla in mice with IFNT
supplementation.
For the jejunum, the two most abundant phyla in IFNT-
supplemented mice, accounting for approximately 99% of
all assigned sequence readings, were Firmicutes (94.5%) and
Bacteroidetes (4.4%) (Figure 2(a)). In control mice, most
abundant phyla were Firmicutes (97.6%) and Bacteroidetes
(1.2%) (Figure 2(a)). For the ileum, the three most abun-
dant phyla in IFNT-supplemented mice were Firmicutes
(95.3%), Candidate division TM7 (2.3%), and Proteobacte-
ria (1.1%) (Figure 2(b)), while in control mice, they were
Firmicutes (97.7%), Proteobacteria (1.5%), and Bacteroidetes
(0.5%) (Figure 2(b)). For the microbiota in the colon, the
threemost abundant phyla in IFNT-supplementedmice were
Bacteroidetes (72.2%), Firmicutes (23.0%), and Proteobacteria
(4.1%) (Figure 2(c)), while they were Bacteroidetes (75.8%),
Firmicutes (18.8%), and Proteobacteria (4.3%) in control mice
(Figure 2(c)). For feces, the three most abundant phyla in
IFNT-supplemented mice were Bacteroidetes (43.6%), Firmi-
cutes (48.1%), and Proteobacteria (5.9%) (Figure 2(d)), while
Bacteroidetes (53.2%), Firmicutes (39.2%), and Proteobacteria
(5.3%) were most abundant for control mice (Figure 2(d)).
For the microbiota of the jejunum, the two most abun-
dant genera in IFNT-supplemented mice, accounting for
approximately 99% of all assigned sequence readings, were
Lactobacillus (94.3%) and S24-7 norank (4.9%) (Figure 3(a)).
In control mice, they were Lactobacillus (97.3%) and S24-
7 norank (1.2%) (Figure 3(a)). For the ileum, the five
most abundant genera in IFNT-supplemented mice were
Lactobacillus (93.3%), Candidatus-Saccharimonas (2.3%),
Allobaculum (1.2%), Desulfovibrio (1.1%), and Enterorhabdus
(0.6%), while they were Lactobacillus (97.3%), Candidatus-
Saccharimonas (0.3%), Allobaculum (0.1%), Desulfovibrio
(1.5%), and Enterorhabdus (0.07%) in control mice (Fig-
ure 3(b)). For the microbiota in the colon, IFNT supplemen-
tation increased the percentages ofBlautia (7.0% versus 5.1%),
Bacteroides (6.4% versus 3.7%), Alloprevotella (5.2% versus
1.3%), and Lactobacillus (4.0% versus 2.5%), compared with
control mice (Figure 3(c)). For the fecal microbiota, IFNT
supplementation increased the percentages of Lactobacillus
(30.0% versus 16.7%), Bacteroides (3.3% versus 1.8%), and
Allobaculum (4.5% versus 0.4%), while decreasing theBlautia
(2.7% versus 6.5%) comparedwith controlmice (Figure 3(d)).
Collectively, IFNT supplementation affects the composi-
tion of intestinal microbiota in mice, especially those for the
colon and feces.
3.4. IFNT Inhibits Expression IL-17 in the Intestine. The
effect of IFNT supplementation on activation of intestinal
innate immunity in mice was further explored, focusing
on the expression of polymeric immunoglobulin receptor
(Pigr), Mucin-4, Cryptidin-1, Cryptidin-4, Cryptidin-5, Il-17,
interferon gamma (Ifn-𝛾), lysozyme (Lyz), and J-chain in the
jejunum, ileum, and colon [18, 21]. In the jejunum, IFNT
supplementation significantly decreased the expression of
Cryptidin-5, Il-17, Ifn-𝛾, and Lyz, while it had little effect on
the expression of the other transcripts (Figure 4(a)). IFNT
supplementation had no significant effect on the expression
of those transcripts in the ileum of mice (Figure 4(b)).
In the colon, IFNT supplementation significantly lowered
the expression of Cryptidin-1 and Il-17 but had little effect
on the expression of the other transcripts (Figure 4(c)).
As IFNT supplementation decreased the expression of Il-17
in the jejunum and colon, we further validated the effect
of IFNT to decrease expression of IL-17 in ETEC infected
mouse model. We found that ETEC infection promotes the
Il-17 expression in the mouse jejunum at 6 hours after
infection (W. Ren and Y. Yin, unpublished results). After two
weeks of IFNT supplementation, expression of Il-17 in the
jejunumwas significantly lower in IFNT-supplementedmice,
compared to that of nonsupplemented mice during ETEC
infection (Figure 4(d)).Thus, IFNT supplementation reduces
the expression of the inflammatory cytokine, IL-17, in the
intestine of mice.
4. Discussion
In this study, although two weeks of IFNT supplementation
increases the mouse feed and water intake but has little effect
on body weight of mice. Results of a previous study revealed
that IFNT supplementation (8𝜇g/kg BW/day) reduces body
weight beginning at 3 weeks after IFNT supplementation
in Zucker Diabetic Fatty rats, while lower dose of IFNT
supplementation (4𝜇g/kg BW/day) has no significant effect
on body weight during 8 weeks of IFNT treatment [19],
indicating that the effect of IFNT on body weight depends
on dosage and duration of IFNT treatment. However, in
a mouse model with high-fat or low-fat diet, 12 weeks of
IFNT treatment does not significantly affect body weight
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Figure 2: Composition of the intestinal microbiota at the phylum level after IFNT supplementation. (a) The microbial composition in the
jejunum. (b)Themicrobial composition in the ileum. (c)Themicrobial composition in the colon. (d)Themicrobial composition in the feces.
[5]. However, IFNT supplementation has little effect on feed
intake and water intake in those investigations [4, 5].
In the present study, IFNT supplementation increases
the microbial diversity in the jejunum and ileum, while
decreasing themicrobial diversity in the feces ofmice.The gut
microbiota affects numerous biological functions [22, 23] and
is linked to the pathogenesis of various diseases, such as obe-
sity [24], cancer [25], and liver cirrhosis [26].The influence of
the gut microbiome on host physiological functions and the
pathogenesis of disease in hosts may result from the activities
of themicrobiome and itsmetabolic products [22]. It is widely
accepted that body weight is associated with the composition
of intestinal microbiome and its metabolic capacity [27]. An
increase in the relative proportion of Firmicutes is linked
to obesity as Firmicutes ferments plant polysaccharides to
produce short-chain fatty acids (SCFA), which provides
additional energy for the host [28]. In phyla, IFNT sup-
plementation decreases the percentage of Firmicutes, while
increasing the Bacteroidetes in the jejunum and ileum.
However, IFNT supplementation increases the percentage
of Firmicutes, while decreasing the Bacteroidetes in the
colon and feces. Thus, IFNT supplementation may regulate
body weight and metabolism through effects on the intesti-
nal microbiota. At the genus level, IFNT supplementation
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decreases the Lactobacillus in the jejunum and ileum but
increases the percentage of Lactobacillus and Bacteroides in
the colon and feces. Lactobacillus has critical roles in the
intestine to combat gastrointestinal bacterial pathogens and
rotaviruses through competitive metabolic interactions and
the production of antimicrobial molecules [29]. Bacteroides
are known for their capacity to metabolize a wide variety of
oligosaccharides from the intestinal luminal, such as xylan,
starch, and host-derived glycans [30]. Thus, results of the
present study suggest that IFNT supplementation affects
those functions of the intestinal microbiome in mice.
IFNT supplementation inhibits intestinal expression of
IL-17, which suggests that IFNT reduces intestinal inflam-
mation. IL-17 is produced by inducible Th17 (iTh17) cells
and natural Th17 (nTh17) cells and regarded as an intestinal
proinflammatory cytokine [31]. IL-17 can activate nuclear
factor 𝜅B (NF-𝜅B) transcription factors, extracellular signal-
regulated protein kinase (ERK1 and ERK2), c-JunN-terminal
kinases (JNK-1 and JNK-2), and mitogen-activated protein
kinases (p38 MAPKs) pathways, leading to upregulation of
expression of inflammatory cytokines, such as IL-6 and IL-
1 [32]. Recent investigations have revealed that mammalian
target of rapamycin (mTOR) is a critical signaling pathway for
Th17 responses and IL-17 expression [33–37]. The mTOR sig-
naling regulates IL-17 expression through hypoxia-inducible
factor 1 𝛼 (HIF-1𝛼) and ribosomal protein S6 kinase (S6K:
S6K1 and S6K2) [37–40]. mTOR signaling activates HIF-
1𝛼, which promotes IL-17 expression by activating ROR𝛾t
(a key transcriptional regulator of Th17 cells) and mediating
degradation of Foxp3 (a key transcriptional regulator of Treg
cells) [40]. S6K1 promotes the expression of early growth
response protein 2 (EGR2), which then inhibits growth factor
independent 1 transcription repressor (GFI1), which can
negatively regulate expression of IL-17 without affecting Rorc
expression [37, 38]. S6K2 (the nuclear-localized counterpart
of S6K1) binds to ROR𝛾t to promote nuclear translocation
of ROR𝛾t, which can complex with HIF-𝛼 and p300 in
the nucleus to promote expression of IL-17 [37–39]. Thus,
the underlying mechanism by which IFNT supplementation
reduces intestinal IL-17 expression is of interest. The effect of
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Figure 4: IFNT supplementation decreases expression of IL-17. (a) Expression of innate immune factors (Pigr, Mucin-4, Cryptidin-1,
Cryptidin-4, Cryptidin-5, Il-17, Ifn-𝛾, Lyz, and J-chain) in the jejunum of mice (𝑛 = 10). (b) Expression of innate immune factors in the
ileum of mice (𝑛 = 10). (c) Expression of innate immune factors in the colon of mice (𝑛 = 10). (d) IFNT decreases expression of IL-17 in
the jejunum of mice following ETEC infection (𝑛 = 10). Data were analyzed using Student’s t-test. An asterisk (∗) indicates a statistically
significant difference between treatment groups (𝑃 < 0.05).
IFNT supplementation to decrease expression of IL-17 in the
intestine indicates a potential therapeutic application of IFNT
to mitigate intestinal inflammatory diseases associated with
expression of IL-17.
In conclusion, IFNT supplementation affects the diversity
and composition of the intestinal microbiota and decreases
expression of IL-17 in mice. The findings from this study are
significant in understanding the physiological and immuno-
logical functions of IFNT in treatment of inflammatory
diseases.
Abbreviations
EGR2: Early growth response protein 2
ERK: Extracellular signal-regulated protein
kinase
ETEC: Enterotoxigenic Escherichia coli
FoxP3: Forkhead box P3
GFI1: Growth factor independent 1 transcription
repressor
HIF-1𝛼: Hypoxia-inducible factor 1𝛼
mTOR: Mammalian target of rapamycin
ROR𝛾t: Retinoic acid receptor-related orphan
receptor gamma t
S6K: Ribosomal protein S6 kinase.
Competing Interests
The authors have no competing interests.
Authors’ Contributions
Wenkai Ren and Bie Tan designed the experiment; Wenkai
Ren and Shuai Chen conducted the experiment; Wenkai
Ren, Liwen Zhang, and Gang Liu analyzed the data; Tarique
Hussain, Xiao Hao, Jie Yin, and Jielin Duan helped in the
experiment;Wenkai Ren wrote the paper; GuoyaoWu, Fuller
W. Bazer, and Yulong Yin revised the paper.
Acknowledgments
This study was supported by National Natural Science
Foundation of China (nos. 31330075, 31372326, and
31272463), National Key Basic Research Program of China
(2013CB127302), and the National Science and Technology
Ministry (2014BAD08B11).
References
[1] K. Brooks and T. E. Spencer, “Biological roles of interferon tau
(IFNT) and type I IFN receptors in elongation of the ovine
conceptus,” Biology of Reproduction, vol. 92, article 47, 2015.
8 Mediators of Inflammation
[2] F. W. Bazer, W. Ying, X. Wang et al., “The many faces of inter-
feron tau,” Amino Acids, vol. 47, no. 3, pp. 449–460, 2015.
[3] A. P. Alexenko, A.D. Ealy, andR.M. Roberts, “The cross-species
antiviral activities of different IFN-tau subtypes on bovine,
murine, and human cells: contradictory evidence for therapeu-
tic potential,” Journal of Interferon & Cytokine Research, vol. 19,
no. 12, pp. 1335–1341, 1999.
[4] K. Hara, K. Shirasuna, F. Usui et al., “Interferon-tau attenuates
uptake of nanoparticles and secretion of interleukin-1𝛽 in
macrophages,”PLoSONE, vol. 9, no. 12, Article ID e113974, 2014.
[5] W. Ying, S. Kanameni, C.-A. Chang et al., “Interferon tau
alleviates obesity-induced adipose tissue inflammation and
insulin resistance by regulatingmacrophage polarization,” PLoS
ONE, vol. 9, no. 6, Article ID e98835, 2014.
[6] J. M. Gonza´lez-Navajas, J. Lee, M. David, and E. Raz, “Immun-
omodulatory functions of type i interferons,” Nature Reviews
Immunology, vol. 12, no. 2, pp. 125–135, 2012.
[7] L. Bosca´, O. G. Bodelo´n, S. Hortelano, A. Casellas, and F. Bosch,
“Anti-inflammatory action of type I interferons deduced from
mice expressing interferon 𝛽,” Gene Therapy, vol. 7, no. 10, pp.
817–825, 2000.
[8] D. J. Gough, N. L. Messina, C. J. P. Clarke, R. W. Johnstone,
and D. E. Levy, “Constitutive type I interferon modulates
homeostatic balance through tonic signaling,” Immunity, vol.
36, no. 2, pp. 166–174, 2012.
[9] J. M. Soos, O. Stu¨ve, S. Youssef et al., “Cutting edge: oral type
I IFN-𝜏 promotes a Th2 bias and enhances suppression of
autoimmune encephalomyelitis by oral glatiramer acetate,”The
Journal of Immunology, vol. 169, no. 5, pp. 2231–2235, 2002.
[10] M. Inoue and M. L. Shinohara, “The role of interferon-𝛽 in the
treatment of multiple sclerosis and experimental autoimmune
encephalomyelitis—in the perspective of inflammasomes,”
Immunology, vol. 139, no. 1, pp. 11–18, 2013.
[11] C. H. Pontzer, F.W. Bazer, andH.M. Johnson, “Antiproliferative
activity of a pregnancy recognition hormone, ovine trophoblast
protein-1,” Cancer Research, vol. 51, no. 19, pp. 5304–5307, 1991.
[12] J. M. Soos, P. S. Subramaniam, A. C. Hobeika, J. Schiffenbauer,
and H. M. Johnson, “The IFN pregnancy recognition hormone
IFN-𝜏 blocks both development and superantigen reactivation
of experimental allergic encephalomyelitis without associated
toxicity,” Journal of Immunology, vol. 155, no. 5, pp. 2747–2753,
1995.
[13] B. Chassaing, O. Koren, J. K. Goodrich et al., “Dietary emul-
sifiers impact the mouse gut microbiota promoting colitis and
metabolic syndrome,”Nature, vol. 519, no. 7541, pp. 92–96, 2015.
[14] C. E. West, H. Renz, M. C. Jenmalm et al., “The gut microbiota
and inflammatory noncommunicable diseases: associations and
potentials for gut microbiota therapies,” Journal of Allergy and
Clinical Immunology, vol. 135, no. 1, pp. 3–14, 2015.
[15] W. Ouyang, J. K. Kolls, and Y. Zheng, “The biological functions
of T helper 17 cell effector cytokines in inflammation,” Immu-
nity, vol. 28, no. 4, pp. 454–467, 2008.
[16] T. Koga, C. M. Hedrich, M. Mizui et al., “CaMK4-
dependent activation of AKT/mTOR and CREM-𝛼 underlies
autoimmunity-associated Th17 imbalance,” Journal of Clinical
Investigation, vol. 124, no. 5, pp. 2234–2245, 2014.
[17] W. Ren, G. Liu, J. Yin et al., “Draft genome sequence of entero-
toxigenic Escherichia coli strain W25K,” Genome Announce-
ments, vol. 2, no. 3, Article ID e00593-14, 2014.
[18] W. Ren, S. Chen, J. Yin et al., “Dietary arginine supplementation
of mice alters the microbial population and activates intestinal
innate immunity,” Journal of Nutrition, vol. 144, no. 6, pp. 988–
995, 2014.
[19] C. D. Tekwe, J. Lei, K. Yao et al., “Oral administration of
interferon tau enhances oxidation of energy substrates and
reduces adiposity in Zucker diabetic fatty rats,” BioFactors, vol.
39, no. 5, pp. 552–563, 2013.
[20] J. Gibson, S. Shokralla, T. M. Porter et al., “Simultaneous
assessment of the macrobiome and microbiome in a bulk
sample of tropical arthropods through DNA metasystematics,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 111, no. 22, pp. 8007–8012, 2014.
[21] W. Ren, J. Duan, J. Yin et al., “Dietary l-glutamine supplemen-
tation modulates microbial community and activates innate
immunity in the mouse intestine,” Amino Acids, vol. 46, no. 10,
pp. 2403–2413, 2014.
[22] W.-J. Lee and K. Hase, “Gut microbiota-generated metabolites
in animal health and disease,” Nature Chemical Biology, vol. 10,
no. 6, pp. 416–424, 2014.
[23] S. Subramanian, S. Huq, T. Yatsunenko et al., “Persistent gut
microbiota immaturity in malnourished Bangladeshi children,”
Nature, vol. 510, no. 7505, pp. 417–421, 2014.
[24] F. F. Anheˆ, D. Roy, G. Pilon et al., “A polyphenol-rich cranberry
extract protects from diet-induced obesity, insulin resistance
and intestinal inflammation in association with increased
Akkermansia spp. population in the gut microbiota of mice,”
Gut, vol. 64, no. 6, pp. 872–883, 2015.
[25] P. Louis, G. L. Hold, and H. J. Flint, “The gut microbiota,
bacterial metabolites and colorectal cancer,” Nature Reviews
Microbiology, vol. 12, no. 10, pp. 661–672, 2014.
[26] N. Qin, F. Yang, A. Li et al., “Alterations of the human gut
microbiome in liver cirrhosis,”Nature, vol. 513, no. 7516, pp. 59–
64, 2014.
[27] P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini,
E. R. Mardis, and J. I. Gordon, “An obesity-associated gut
microbiomewith increased capacity for energy harvest,”Nature,
vol. 444, no. 7122, pp. 1027–1031, 2006.
[28] R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, “Microbial
ecology: human gut microbes associated with obesity,” Nature,
vol. 444, no. 7122, pp. 1022–1023, 2006.
[29] V. Lie´vin-Le Moal and A. L. Servin, “Anti-infective activities of
Lactobacillus strains in the human intestinal microbiota: from
probiotics to gastrointestinal anti- infectious biotherapeutic
agents,”ClinicalMicrobiology Reviews, vol. 27, no. 2, pp. 167–199,
2014.
[30] A. Marcobal and J. L. Sonnenburg, “Human milk oligosaccha-
ride consumption by intestinal microbiota,” Clinical Microbiol-
ogy and Infection, vol. 18, supplement 4, pp. 12–15, 2012.
[31] A. G. Shabgah, E. Fattahi, and F. Z. Shahneh, “Interleukin-
17 in human inflammatory diseases,” Postepy Dermatologii i
Alergologii, vol. 31, no. 4, pp. 256–261, 2014.
[32] S. H. Chang and C. Dong, “Signaling of interleukin-17 family
cytokines in immunity and inflammation,” Cellular Signalling,
vol. 23, no. 7, pp. 1069–1075, 2011.
[33] M. F. Gulen, Z. Kang, K. Bulek et al., “The receptor SIGIRR sup-
pressesTh17 cell proliferation via inhibition of the interleukin-1
receptor pathway and mTOR kinase activation,” Immunity, vol.
32, no. 1, pp. 54–66, 2010.
[34] J. S. Kim, T. Sklarz, L. B. Banks et al., “Natural and inducible
TH17 cells are regulated differently by Akt and mTOR path-
ways,” Nature Immunology, vol. 14, no. 6, pp. 611–618, 2013.
Mediators of Inflammation 9
[35] Y. Park, H.-S. Jin, J. Lopez et al., “TSC1 regulates the balance
between effector and regulatory T cells,”The Journal of Clinical
Investigation, vol. 123, no. 12, pp. 5165–5178, 2013.
[36] S. Nagai, Y. Kurebayashi, and S. Koyasu, “Role of PI3K/Akt and
mTORcomplexes inTh17 cell differentiation,”Annals of theNew
York Academy of Sciences, vol. 1280, no. 1, pp. 30–34, 2013.
[37] W. Ren, J. Yin, J. Duan et al., “mTORC1 signaling and IL-17
expression: defining pathways and possible therapeutic targets,”
European Journal of Immunology, vol. 46, no. 2, pp. 291–299,
2016.
[38] Y. Kurebayashi, S. Nagai, A. Ikejiri et al., “PI3K-Akt-mTORC1-
S6K1/2 axis controls Th17 differentiation by regulating Gfi1
expression and nuclear translocation of ROR𝛾,” Cell Reports,
vol. 1, no. 4, pp. 360–373, 2012.
[39] L. Z. Shi, R.Wang, G.Huang et al., “HIF1𝛼-dependent glycolytic
pathway orchestrates a metabolic checkpoint for the differen-
tiation of TH17 and Treg cells,” The Journal of Experimental
Medicine, vol. 208, no. 7, pp. 1367–1376, 2011.
[40] E. V. Dang, J. Barbi, H.-Y. Yang et al., “Control of TH17/Treg
balance by hypoxia-inducible factor 1,” Cell, vol. 146, no. 5, pp.
772–784, 2011.
